Theravance Biopharma (TBPH) EBIT Margin (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of EBIT Margin data on file, last reported at 53.58% in Q1 2026.

• On a quarterly basis, EBIT Margin rose 4022.0% year-over-year to 53.58% in Q1 2026; TTM through Mar 2026 was 1.23%, a 7811.0% increase from a year earlier, with the FY2025 full-year figure at 48.03%, up 2490.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 53.58%, down from 43.61% in the prior quarter.
• Over the last five years, EBIT Margin for TBPH reached as high as 43.61% in Q4 2025 and fell as low as 291.77% in Q1 2022.
• Historically, EBIT Margin has averaged 95.44% across 5 years, with a median of 73.44% in 2022.
• Across the five-year window, EBIT Margin jumped 33292 bps in 2022 and slumped 1653 bps in 2025, its largest moves.
• Year by year, EBIT Margin stood at 119.0% in 2022, then soared by 70 bps to 35.53% in 2023, then slumped by 38 bps to 49.06% in 2024, then surged by 189 bps to 43.61% in 2025, then slumped by 223 bps to 53.58% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 53.58% in Q1 2026, 43.61% in Q4 2025, and 32.29% in Q3 2025.